Crystal methamphetamine, its analogues, and HIV infection: Medical and psychiatric aspects of a new epidemic

Clinical Infectious Diseases

Volumn 38, Issue 6, 2004, Pages 890-894

  Urbina, Antonio ^a,b   Jones, Kristina ^c,d  

^a NEW YORK MEDICAL COLLEGE   (United States)

^b ST VINCENT S HOSPITAL   (United States)

^c WEILL CORNELL MEDICAL COLLEGE   (United States)

^d NEW YORK PRESBYTERIAN HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

3,4 METHYLENEDIOXYMETHAMPHETAMINE; AMFEBUTAMONE; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; ANTIDEPRESSANT AGENT; BROMOCRIPTINE; DOPAMINE RECEPTOR STIMULATING AGENT; METHAMPHETAMINE; METHYLPHENIDATE; NEUROLEPTIC AGENT; PERGOLIDE; STREET DRUG;

AUDITORY HALLUCINATION; CAUSE OF DEATH; CLINICAL TRIAL; DEPRESSION; DISEASE ASSOCIATION; DOPAMINERGIC SYSTEM; DRUG DEPENDENCE; EPIDEMIC; HOMOSEXUALITY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERTENSION; HYPERTHERMIA; INFECTION RATE; MENTAL DISEASE; NEUROTOXICITY; NONHUMAN; PARANOIA; PRIORITY JOURNAL; PSYCHOSIS; REVIEW; RHABDOMYOLYSIS; SEXUAL BEHAVIOR; STROKE; VIOLENCE; VIRUS TRANSMISSION; ADDICTION; ARTICLE; DRUG ABUSE; DRUG EFFECT; DRUG INTERACTION; DRUG TOLERANCE; MALE; METABOLISM; PSYCHOLOGICAL ASPECT;

AMPHETAMINE-RELATED DISORDERS; ANTI-HIV AGENTS; DISEASE OUTBREAKS; DRUG INTERACTIONS; DRUG TOLERANCE; HIV INFECTIONS; HOMOSEXUALITY; HUMANS; MALE; METHAMPHETAMINE; SEXUAL BEHAVIOR; STREET DRUGS; SUBSTANCE-RELATED DISORDERS;

EID: 1642363158     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/381975     Document Type: Review

References (56)

1. Rawson R, Anglin M, Ling W. Will the methamphetamine problem go away? J Addict Dis 2002; 21:5-19.
2. Halkitis PN, Parsons JT, Stirratt MJ. A double epidemic: crystal methamphetamine drug use in relation to HIV transmission among gay men. J Homosex 2001; 41:17-35.
3. Mansergh G, Colfax GN, Marks G, Rader M, Guzman R, Buchbinder S. The Circuit Party Men's Health Survey: findings and implications for gay and bisexual men. Am J Public Health 2001; 91:953-8.
4. Shoptaw S, Reback CJ, Freese TE. Patient characteristics, HIV sero-status, and risk behaviors among gay and bisexual males seeking treatment for methamphetamine abuse and dependence in Los Angeles. J Addict Dis 2002; 21:91-105.
5. Klitzman RL, Pope HG, Hudson JI. MDMA ("ecstasy") abuse and high-risk sexual behaviors among 169 gay and bisexual men. Am J Psychiatry 2000; 157:1162-4.
6. Bernstein KT, Tulloch R, Montes J, et al. Outbreak of syphilis among men who have sex with men - Southern California, 2000. MMWR Morb Mortal Wkly Rep 2001; 50:117-20.
7. Lynch J, House MA. Cardiovascular effects of methamphetamine. J Cardiovasc Nurs 1992; 6:12-8.
8. Albertson TE, Derlet RW, Van Hoozen BE. Methamphetamine and the expanding complications of amphetamines. West J Med 1999; 170:214-9.
9. Richards JR, Johnson EB, Stark RW, Derlet RW. Methamphetamine abuse and rhabdomyolysis in the ED: a 5-year study. Am J Emerg Med 1999; 17:681-5.
10. Varner KJ, Ogden BA, Delcarpio J, Meleg-Smith S. Cardiovascular responses elicited by the "binge" administration of methamphetamine. J Pharmacol Exp Ther 2002; 301:152-9.
11. Perez JA Jr, Arsura EL, Strategos S. Methamphetamine-related stroke: four cases. J Emerg Med 1999; 17:469-71.
12. Hong R, Matsuyama E, Nur K. Cardiomyopathy associated with the smoking of crystal methamphetamine. JAMA 1991; 265:1152-4.
13. House RV, Thomas PT, Bhargava HN. Comparison of immune functional parameters following in vitro exposure to natural and synthetic amphetamines. Immunopharmacol Immunotoxicol 1994; 16:1-21.
14. Bagasra O, Pomerantz RJ. Human immunodeficiency virus type 1 provirus is demonstrated in peripheral blood monocytes in vivo: a study utilizing an in situ polymerase chain reaction. AIDS Res Hum Retroviruses 1993; 9:69-76.
15. Venker D. Crystal methamphetamine and the denial patient. Iowa Dent J 1999; 85:34.
16. Richards JR, Brofeldt BT. Patterns of tooth wear associated with methamphetamine use. J Periodontol 2000; 71:1371-4.
17. Weland M, ed. Crook's bad teeth costing taxpayers. Kootenai County News 20 January 2002.
18. Buchanan JF, Brown CR. "Designer drugs": a problem in clinical toxicology. Med Toxicol Adverse Drug Exp 1988; 3:1-17.
19. Ramamoorthy Y, Tyndale RF, Sellers EM. Cytochrome P450 2D6.1 and cytochrome P450 2D6.10 differ in catalytic activity for multiple substrates. Pharmacogenetics 2001; 11:477-87.
20. Brosen K, Gram LF. Clinical significance of the sparteine/debrisoquine oxidation polymorphism. Eur J Clin Pharmacol 1989; 36:537-47.
21. Pritzker D, Kanungo A, Kilicarslan T, Tyndale RF, Sellers EM. Designer drugs that are potent inhibitors of CYP2D6. J Clin Psychopharmacol 2002; 22:330-2.
22. Hales G, Roth N, Smith D. Possible fatal interaction between protease inhibitors and methamphetamine. Antivir Ther 2000; 5:19.
23. Henry JA, Hill IR. Fatal interaction between ritonavir and MDMA. Lancet 1998; 352:1751-2.
24. Baker R, Bowers M. Ritonavir and ecstasy. BETA 1997; March:5.
25. Melega WP, Williams AE, Schmitz DA, DiStefano EW, Cho AK. Pharmacokinetic and pharmacodynamic analysis of the actions of D-amphetamine and D-methamphetamine on the dopamine terminal. J Pharmacol Exp Ther 1995; 274:90-6.
26. Woolverton WL, Ricaurte GA, Forno LS, Seiden LS. Long-term effects of chronic methamphetamine administration in rhesus monkeys. Brain Res 1989; 486:73-8.
27. Volkow ND, Chang L, Wang GJ, et al. Association of dopamine transporter reduction with psychomotor impairment in methamphetamine abusers. Am J Psychiatry 2001; 158:377-82.
28. Volkow ND, Chang L, Wang GJ, et al. Loss of dopamine transporters in methamphetamine abusers recovers with protracted abstinence. J Neurosci 2001; 21:9414-8.
29. Berger JR, Arendt G. HIV dementia: the role of the basal ganglia and dopaminergic systems. J Psychopharmacol 2000; 14:214-21.
30. Nath A. Human immunodeficiency virus (HIV) proteins in neuropathogenesis of HIV dementia. J Infect Dis 2002; 186(Suppl 2):S193-8.
31. Minagar A, Shapshak P, Fujimura R, Ownby R, Heyes M, Eisdorfer C. The role of macrophage/microglia and astrocytes in the pathogenesis of three neurologic disorders: HIV-associated dementia, Alzheimer disease, and multiple sclerosis. J Neurol Sci 2002; 202:13-23.
32. Nath A, Haughey NJ, Jones M, Anderson C, Bell JE, Geiger JD. Synergistic neurotoxicity by human immunodeficiency virus proteins Tat and gp120: protection by memantine. Ann Neurol 2000; 47:186-94.
33. Nath A, Anderson C, Jones M, et al. Neurotoxicity and dysfunction of dopaminergic systems associated with AIDS dementia. J Psychopharmacol 2000; 14:222-7.
34. Lopez OL, Smith G, Meltzer CC, Becker JT. Dopamine systems in human immunodeficiency virus-associated dementia. Neuropsychiatry Neuropsychol Behav Neurol 1999; 12:184-92.
35. Sekine Y, Minabe Y, Ouchi Y, et al. Association of dopamine transporter loss in the orbitofrontal and dorsolateral prefrontal cortices with methamphetamine-related psychiatric symptoms. Am J Psychiatry 2003; 160:1699-701.
36. Nath A, Hauser KF, Wojna V, et al. Molecular basis for interactions of HIV and drugs of abuse. J Acquir Immune Defic Syndr 2002; 31(Suppl 2):S62-9.
37. Nath A, Maragos WF, Avison MJ, Schmitt FA, Berger JR. Acceleration of HIV dementia with methamphetamine and cocaine. J Neurovirol 2001; 7:66-71.
38. Grant I, Heaton RK, Dawson LK, Marcotte TD. Abuse of methamphetamine and cocaine may enhance HIV associated neurotoxicity. Arch Clin Neuropsychol 1999; 14:130.
39. Gavrilin MA, Mathes LE, Podell M. Methamphetamine enhances cell-associated feline immunodeficiency virus replication in astrocytes. J Neurovirol 2002; 8:240-9.
40. Cho AK, Melega WP, Kuczenski R, Segal DS. Relevance of pharmacokinetic parameters in animal models of methamphetamine abuse. Synapse 2001; 39:161-6.
41. Vandevenne M, Vandenbussche H, Verstraeta A. Detection time of drugs of abuse in urine. Acta Clin Belg 2000; 55:323-3.
42. Cho AK, Melega WP. Patterns of methamphetamine abuse and their consequences. J Addict Dis 2002; 21:21-34.
43. Milne D. Experts desperately seeking meth abuse prevention, treatment. Psychiatr News 2003; 38:12.
44. Anglin M, Burke C, Perrochet B, Stamper E, Dawud-Noursi S. History of the methamphetamine problem. J Psychoactive Drugs 2000; 32:137-41.
45. Post RM, Kopanda RT. Cocaine, kindling and psychosis. Am J Psychiatry 1976; 133:627-34.
46. Lemere F. The danger of amphetamine dependency. Am J Psychiatry 1966; 123:569-72.
47. Seiden LS, Sabol KE. Methamphetamine and methylenedioxymethamphetamine neurotoxicity: possible mechanisms of cell destruction. NIDA Res Monogr 1996; 163:251-76.
48. Kalechstein AD, Newton TF, Longshore D, Anglin MD, van Gorp WG, Gawin FH. Psychiatric comorbidity of methamphetamine dependence in a forensic sample. J Neuropsychiatry Clin Neurosci 2000; 12:480-4.
49. Rawson R, Huber A, Brethen P, Obert J, Shoptaw S, Ling W. Status of methamphetamine users 2-5 years after outpatient treatment. J Addict Dis 2002; 21:107-19.
50. Jackson JG. Hazards of smokable methamphetamine [letter]. New Engl J Med 1989; 321:907.
51. + men who have sex with men. J Subst Abuse Treat 2002; 22:149-56.
52. Moscoviz H, Brookoff D, Nelson L. A randomized trial of bromocriptine for cocaine users presenting to the emergency department. J Gen Intern Med 1993; 8:1-4.
53. Malcolm R, Kajdasz DK, Herron J, Anton RF, Brady KT. A double-blind, placebo-controlled outpatient trial of pergolide for cocaine dependence. Drug Alcohol Depend 2000; 60:161-8.
54. Batki SL. Review: dopamine agonists are not effective for cocaine dependence. Evid Based Ment Health 2002; 5:82-3.
55. Grabowski J, Roache JD, Schmitz JM, Rhoades H, Carson D, Korszun A. Replacement medication for cocaine dependence: methylphenidate. J Clin Psychopharmacol 1997; 17:485-8.
56. Kosten TR, O'Connor PG. Management of drug and alcohol withdrawal. N Engl J Med 2003; 348:1786-95.